Psyence Biomedical Ltd. (PBM) EBITDA (2023 - 2025)
Psyence Biomedical (PBM) posted quarterly EBITDA of -$1.5 million for Q3 2025, down 230.0% year-over-year from $1.2 million in Q3 2024, and down 230.0% quarter-over-quarter from $1.2 million in Q3 2024.
Psyence Biomedical Ltd. (PBM) EBITDA (2023 - 2025) Analysis & Trends
Psyence Biomedical's EBITDA history runs 3 years deep, the most recent figure standing at -$1.5 million for Q3 2025.
- In Q3 2025, EBITDA fell 230.0% year-over-year to -$1.5 million; the TTM figure through Sep 2025 stood at -$3.7 million (changed N/A YoY), while the FY2026 annual figure was -$6.9 million, down 88.35% from the prior year.
- EBITDA for Q3 2025 stood at -$1.5 million, down from $1.2 million in the prior quarter.
- The five-year high for EBITDA was $1.2 million in Q3 2024, with the low at -$3.2 million in Q1 2023.
- The 3-year median for EBITDA is -$842612.5 (2023), against an average of -$932831.2.
- The sharpest annual moves came in 2024 and 2025: EBITDA surged 758.95% in 2024, then plunged 230.0% in 2025.
- Psyence Biomedical's EBITDA stood at -$176165.0 in 2023, then soared by 758.95% to $1.2 million in 2024, then slumped by 230.0% to -$1.5 million in 2025.
- Business Quant data shows PBM's EBITDA at -$1.5 million in Q3 2025, $1.2 million in Q3 2024, and -$176165.0 in Q3 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.51 Mn |
| Sep 30, 2024 | 1.16 Mn |
| Sep 30, 2023 | -176,165.00 |
| Mar 31, 2023 | -3.21 Mn |